ESMO Conference Coverage
Filter News By:
Featured News
View all
More News
(Innate Pharma) Dec 3, 2020 - Innate Pharma SA today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from Dec. 9-12, 2020.
(Immunocore) Dec 3, 2020 - Immunocore today announced that it will present new clinical results on tebentafusp (IMCgp100) at the ESMO IO Virtual Congress on the 12th December.
(Evaluate Vantage) Sept 24, 2020 - Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves. Pre-conference deals were ultimately responsible for the substantial...
(MedPage Today) Sept 23, 2020 - An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.
(Evaluate Vantage) Sept 23, 2020 - The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.
(BioPharma Dive) Sept 22, 2020 - Regeneron and partner Sanofi on Monday disclosed new results showing their immunotherapy Libtayo helped patients newly diagnosed with advanced non-small cell lung cancer live longer than those given...
(ESMO 2020) Sept 22, 2020 - No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom radical uterine procedure (mostly radical hysterectomy) was completed or...
(MedPage Today) Sept 21, 2020 - An investigational inhibitor of apoptosis proteins (IAPs) extended survival in locally advanced head and neck squamous cell carcinoma (SCC) when added to standard chemoradiotherapy, according to an updated...
(U.S. News & World Report/HealthDay News) Sept, 22, 2020 - People with cancer are at increased risk for severe COVID-19. Now, a preliminary study suggests that certain cancer therapies may heighten those odds even further.
(Merck) Sept 21, 2020 - KEYTRUDA plus chemotherapy demonstrated superior overall survival and progression-free survival versus chemotherapy in these patients regardless of PD-L1 expression status and tumor histology. Results from...
ESMO Clinical Briefs
In the phase 3 CheckMate-9ER trial of patients with advanced renal cell carcinoma (aRCC), first-line treatment with nivolumab plus cabozantinib demonstrated superior progression-free survival (PFS), overall survival (OS), and objective response rates (ORR) compared with sunitinib.
In the KEYNOTE-177 study, reported at the ESMO 2020 Virtual Meeting, pembrolizumab monotherapy significantly improved progression-free survival (PFS) vs standard chemotherapy as first-line treatment in patients with microsatellite instability-high and/or deficient mismatch repair metastatic colorectal cancer (mCRC).
The phase 3 PROfound trial reported favorable progression-free survival (PFS) outcomes for olaparib vs enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent.
In a study reported at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 ESMO Meeting, first-line cemiplimab monotherapy significantly improved overall survival (OS) and progression-free (PFS) vs platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 ≥50%. Despite a high crossover rate, the study provided a rationale for cemiplimab as a new treatment option for this patient population.
At ESMO Virtual Congress 2020, the results from three randomized phase 3 clinical trials — CheckMate 649, ATTRACTION-4, and KEYNOTE-590 — made one thing clear: Immunotherapy benefits patients with gastric and esophageal cancers. As for the adjuvant setting, which had no standard of care, the results from the phase 3 CheckMate 577 trial point to nivolumab as a new option.
PARP inhibition continues to steal the spotlight in advanced ovarian cancer, even in the absence of pivotal trial data. Findings presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 showed a significant benefit for PARP inhibition earlier in the cancer pathway, offering hope for more long-term survivors, while other treatment paradigms such as immunotherapy failed again to make headway against the disease.
At ESMO Virtual Congress 2020, the results from two randomized phase 3 trials monarchE and ASCENT showed that success is possible for breast cancer subtypes that have long eluded treatment. However, the results of IMpassion131, IMpassion130, and IMpassion031 for atezolizumab were a mixed bag.

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?…

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat…

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a…

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL…

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib